Tenax Long Term Debt vs Current Deferred Revenue Analysis

TENX Stock

USD 3.84 0.05 1.32%

Tenax Therapeutics financial indicator trend analysis is much more than just breaking down Tenax Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tenax Therapeutics is a good investment. Please check the relationship between Tenax Therapeutics Long Term Debt and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Long Term Debt vs Current Deferred Revenue

Long Term Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tenax Therapeutics Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Tenax Therapeutics' Long Term Debt and Current Deferred Revenue is 0.9. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Tenax Therapeutics, assuming nothing else is changed. The correlation between historical values of Tenax Therapeutics' Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Tenax Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Long Term Debt i.e., Tenax Therapeutics' Long Term Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.9

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Long Term Debt

Long-term debt is a debt that Tenax Therapeutics has held for over one year. Long-term debt appears on Tenax Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Tenax Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Tenax Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tenax Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.At this time, Tenax Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 0.49 in 2024, whereas Selling General Administrative is likely to drop 4,755 in 2024.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	32.7M	11.1M	8.2M	8.4M
Depreciation And Amortization	363.8K	122.5K	7.6K	7.2K

Other Operating Expenses Depreciation And Amortization

Tenax Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Common Stock Total Equity	Property Plant And Equipment Gross	Non Currrent Assets Other	Property Plant Equipment	Other Assets	Long Term Debt
Total Assets		-0.22	0.19	0.13	1.0	-0.17	-0.99	0.27	-0.14	0.99	0.76	1.0	0.43	0.91	-0.08	0.11	0.89	1.0	0.26	-0.19	-0.19	-0.2	-0.53	-0.39	0.02	-0.31
Short Long Term Debt Total	-0.22		-0.04	-0.04	-0.26	0.72	0.28	0.33	-0.03	-0.23	-0.13	-0.25	-0.18	0.17	-0.18	-0.43	0.16	-0.25	-0.22	-0.1	-0.1	0.73	0.09	0.35	-0.16	0.56
Other Current Liab	0.19	-0.04		0.83	0.16	-0.2	-0.14	0.05	-0.13	0.14	0.33	0.16	-0.05	0.11	-0.13	0.01	0.38	0.16	-0.17	-0.18	-0.18	-0.18	-0.06	-0.35	0.05	-0.06
Total Current Liabilities	0.13	-0.04	0.83		0.11	-0.29	-0.1	-0.19	0.36	0.1	0.16	0.1	0.26	0.01	0.37	0.25	0.34	0.11	-0.03	-0.33	-0.33	-0.23	0.02	-0.27	-0.16	0.02
Total Stockholder Equity	1.0	-0.26	0.16	0.11		-0.2	-1.0	0.25	-0.14	0.99	0.76	1.0	0.43	0.9	-0.07	0.13	0.87	1.0	0.27	-0.18	-0.18	-0.23	-0.53	-0.4	0.03	-0.33
Property Plant And Equipment Net	-0.17	0.72	-0.2	-0.29	-0.2		0.2	0.46	-0.31	-0.17	-0.07	-0.2	-0.41	0.17	-0.51	-0.56	0.11	-0.2	-0.22	0.14	0.14	0.98	0.03	0.52	0.08	0.6
Net Debt	-0.99	0.28	-0.14	-0.1	-1.0	0.2		-0.22	0.1	-1.0	-0.74	-1.0	-0.44	-0.88	0.04	-0.16	-0.85	-1.0	-0.28	0.19	0.19	0.24	0.52	0.39	-0.01	0.34
Retained Earnings	0.27	0.33	0.05	-0.19	0.25	0.46	-0.22		-0.53	0.24	0.28	0.23	-0.15	0.47	-0.54	-0.93	0.39	0.23	-0.27	0.6	0.6	0.37	-0.18	0.27	0.67	0.45
Accounts Payable	-0.14	-0.03	-0.13	0.36	-0.14	-0.31	0.1	-0.53		-0.11	-0.38	-0.12	0.59	-0.24	0.9	0.52	-0.11	-0.11	0.05	-0.31	-0.3	-0.22	0.23	-0.05	-0.42	-0.19
Cash	0.99	-0.23	0.14	0.1	0.99	-0.17	-1.0	0.24	-0.11		0.75	1.0	0.44	0.91	-0.05	0.13	0.87	1.0	0.27	-0.19	-0.19	-0.2	-0.53	-0.37	0.01	-0.32
Non Current Assets Total	0.76	-0.13	0.33	0.16	0.76	-0.07	-0.74	0.28	-0.38	0.75		0.75	-0.15	0.71	-0.24	0.0	0.72	0.75	0.16	-0.12	-0.12	-0.14	-0.66	-0.37	0.17	-0.19
Cash And Short Term Investments	1.0	-0.25	0.16	0.1	1.0	-0.2	-1.0	0.23	-0.12	1.0	0.75		0.44	0.9	-0.06	0.14	0.87	1.0	0.26	-0.21	-0.21	-0.23	-0.53	-0.41	0.0	-0.34
Common Stock Shares Outstanding	0.43	-0.18	-0.05	0.26	0.43	-0.41	-0.44	-0.15	0.59	0.44	-0.15	0.44		0.29	0.6	0.34	0.34	0.44	0.29	-0.18	-0.17	-0.35	0.04	-0.07	-0.21	-0.28
Non Current Liabilities Total	0.91	0.17	0.11	0.01	0.9	0.17	-0.88	0.47	-0.24	0.91	0.71	0.9	0.29		-0.26	-0.14	0.94	0.9	0.12	-0.18	-0.18	0.14	-0.5	-0.25	0.0	-0.06
Other Current Assets	-0.08	-0.18	-0.13	0.37	-0.07	-0.51	0.04	-0.54	0.9	-0.05	-0.24	-0.06	0.6	-0.26		0.57	-0.14	-0.05	0.3	-0.21	-0.21	-0.44	0.13	0.0	-0.28	-0.24
Other Stockholder Equity	0.11	-0.43	0.01	0.25	0.13	-0.56	-0.16	-0.93	0.52	0.13	0.0	0.14	0.34	-0.14	0.57		-0.07	0.15	0.37	-0.68	-0.68	-0.48	-0.02	-0.42	-0.67	-0.58
Total Liab	0.89	0.16	0.38	0.34	0.87	0.11	-0.85	0.39	-0.11	0.87	0.72	0.87	0.34	0.94	-0.14	-0.07		0.87	0.13	-0.27	-0.27	0.09	-0.46	-0.29	-0.04	-0.02
Total Current Assets	1.0	-0.25	0.16	0.11	1.0	-0.2	-1.0	0.23	-0.11	1.0	0.75	1.0	0.44	0.9	-0.05	0.15	0.87		0.27	-0.21	-0.21	-0.23	-0.52	-0.41	-0.01	-0.34
Short Term Debt	0.26	-0.22	-0.17	-0.03	0.27	-0.22	-0.28	-0.27	0.05	0.27	0.16	0.26	0.29	0.12	0.3	0.37	0.13	0.27		0.04	0.03	-0.23	-0.16	0.27	0.05	-0.36
Common Stock	-0.19	-0.1	-0.18	-0.33	-0.18	0.14	0.19	0.6	-0.31	-0.19	-0.12	-0.21	-0.18	-0.18	-0.21	-0.68	-0.27	-0.21	0.04		1.0	0.03	0.06	0.63	0.95	0.06
Common Stock Total Equity	-0.19	-0.1	-0.18	-0.33	-0.18	0.14	0.19	0.6	-0.3	-0.19	-0.12	-0.21	-0.17	-0.18	-0.21	-0.68	-0.27	-0.21	0.03	1.0		0.03	0.06	0.62	0.95	0.06
Property Plant And Equipment Gross	-0.2	0.73	-0.18	-0.23	-0.23	0.98	0.24	0.37	-0.22	-0.2	-0.14	-0.23	-0.35	0.14	-0.44	-0.48	0.09	-0.23	-0.23	0.03	0.03		0.15	0.48	-0.04	0.61
Non Currrent Assets Other	-0.53	0.09	-0.06	0.02	-0.53	0.03	0.52	-0.18	0.23	-0.53	-0.66	-0.53	0.04	-0.5	0.13	-0.02	-0.46	-0.52	-0.16	0.06	0.06	0.15		0.22	-0.1	0.14
Property Plant Equipment	-0.39	0.35	-0.35	-0.27	-0.4	0.52	0.39	0.27	-0.05	-0.37	-0.37	-0.41	-0.07	-0.25	0.0	-0.42	-0.29	-0.41	0.27	0.63	0.62	0.48	0.22		0.48	0.31
Other Assets	0.02	-0.16	0.05	-0.16	0.03	0.08	-0.01	0.67	-0.42	0.01	0.17	0.0	-0.21	0.0	-0.28	-0.67	-0.04	-0.01	0.05	0.95	0.95	-0.04	-0.1	0.48		0.0
Long Term Debt	-0.31	0.56	-0.06	0.02	-0.33	0.6	0.34	0.45	-0.19	-0.32	-0.19	-0.34	-0.28	-0.06	-0.24	-0.58	-0.02	-0.34	-0.36	0.06	0.06	0.61	0.14	0.31	0.0

Click cells to compare fundamentals

Tenax Therapeutics Account Relationship Matchups

Tenax Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.4M	6.9M	6.0M	3.4M	11.7M	15.5M
Other Current Liab	760.0K	1.2M	597.1K	655.7K	1.0M	790.7K
Total Current Liabilities	2.5M	2.1M	1.6M	1.8M	3.6M	3.8M
Total Stockholder Equity	3.8M	4.6M	4.2M	1.5M	8.1M	12.7M
Property Plant And Equipment Net	8.5K	176.0K	64.8K	294.8K	186.7K	0.0
Net Debt	(4.7M)	(5.9M)	(5.3M)	(1.3M)	(9.3M)	(9.8M)
Retained Earnings	(236.2M)	(246.0M)	(278.5M)	(289.5M)	(297.3M)	(282.4M)
Accounts Payable	1.7M	757.9K	859.6K	448.4K	2.1M	2.2M
Cash	4.9M	6.3M	5.6M	2.1M	9.8M	9.6M
Non Current Assets Total	184.4K	73.2K	303.2K	196.2K	1.1K	1.1K
Cash And Short Term Investments	5.4M	6.7M	5.6M	2.1M	9.8M	10.0M
Common Stock Shares Outstanding	3.9K	4.6K	12.9K	18.4K	248.4K	260.9K
Liabilities And Stockholders Equity	6.4M	6.9M	6.0M	3.4M	11.7M	15.5M
Non Current Liabilities Total	749.8K	60.4K	124.2K	183.6K	64.2K	0.0
Other Current Assets	781.0K	82.6K	105.1K	345.9K	1.9M	2.0M
Other Stockholder Equity	239.9M	250.6M	282.7M	291.0M	305.4M	320.6M
Total Liab	2.6M	2.2M	1.7M	1.9M	3.6M	2.8M
Total Current Assets	6.2M	6.8M	5.7M	3.2M	11.7M	10.5M
Common Stock	674.0	1.3K	2.5K	4.6K	30.0	28.5
Common Stock Total Equity	141.0	379.0	674.0	1.3K	1.1K	1.1K
Property Plant And Equipment Gross	8.5K	176.0K	6.0K	294.8K	186.7K	0.0
Accumulated Other Comprehensive Income	(16.2K)	516.0	458.0	(70.0)	(63.0)	(66.15)
Property Plant Equipment	8.5K	6.6K	64.8K	294.8K	265.3K	172.3K
Net Tangible Assets	11.8M	3.8M	4.6M	4.2M	3.8M	3.6M
Retained Earnings Total Equity	(213.5M)	(227.8M)	(236.2M)	(246.0M)	(221.4M)	(232.5M)
Capital Surpluse	222.4M	239.6M	239.9M	250.6M	288.2M	226.5M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tenax Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tenax Therapeutics' short interest history, or implied volatility extrapolated from Tenax Therapeutics options trading.

Currently Active Assets on Macroaxis

LAAC	Lithium Americas Corp
F	Ford Motor
CHPT	ChargePoint Holdings
AXL	American Axle Manufacturing
ICLN	iShares Global Clean

When determining whether Tenax Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tenax Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tenax Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tenax Therapeutics Stock:

How To Invest In Tenax

Details

Is Tenax Stock a good investment?

Details

What is Tenax Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Tenax Stock analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.

Is Tenax Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenax Therapeutics. If investors know Tenax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenax Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(31.04)

Return On Assets

(0.68)

Return On Equity

(1.61)

The market value of Tenax Therapeutics is measured differently than its book value, which is the value of Tenax that is recorded on the company's balance sheet. Investors also form their own opinion of Tenax Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenax Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenax Therapeutics' market value can be influenced by many factors that don't directly affect Tenax Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tenax Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenax Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenax Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tenax Long Term Debt vs Current Deferred Revenue Analysis

Long Term Debt vs Current Deferred Revenue

Long Term Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Long Term Debt

Current Deferred Revenue

Tenax Therapeutics fundamental ratios Correlations

Tenax Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tenax Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Tenax Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Other Stockholder Equity	- 0.93	Retained Earnings